Back

Ticagrelor versus clopidogrel in acute coronary syndrome patients with concurrent high ischemic and high bleeding risk after drug-eluting stent implantation

28 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Contemporary pharmacotherapy after acute coronary syndromes: beta-blockers, lipids, and platelet inhibition Antiplatelet Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Miaohan Qiu

General Hospital of Northern Theater Command, Shenyang (China)

7 More presentations in this session

Presentation thumbnail
Effect of beta-blockers on cardiovascular hospitalisation after myocardial infarction: A substudy of the BETAMI-DANBLOCK trial.
Doctor H. Caglar (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Troponin-stratified outcomes of extended clopidogrel monotherapy versus dual antiplatelet therapy in acute coronary syndrome: insights from the OPT-BIRISK randomized trial
Professor M. Qiu (Shenyang, CN)
Abstract Slides
Presentation thumbnail
Coordinated post-myocardial infarction care versus the PCSK9 modulator drug program: a comparative outcomes study
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Long-term effect of beta-blockers after myocardial infarction with preserved left ventricular ejection fraction in a per protocol analysis of the REDUCE-AMI trial
Professor T. Jernberg (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Long-term clinical outcomes of beta-blocker therapy in elderly patients with preserved left ventricular function after percutaneous coronary intervention for acute myocardial infarction
Assistant Professor J. Choe (Pusan, KR)
Abstract Slides

Access the full session

Session thumbnail
Contemporary pharmacotherapy after acute coronary syndromes: beta-blockers, lipids, and platelet inhibition

The Event

Event poster

ESC Congress 2026

28 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Ticagrelor or prasugrel in patients with acute coronary syndrome and high bleeding risk
27 August 2022
thumbnail
Congress Presentation
Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus
17 April 2021
thumbnail
Congress Presentation
Cost-effectiveness of clopidogrel versus ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome
27 August 2022
thumbnail
Congress Session
Meet the Experts: de-escalating DAPT in acute coronary syndrome patients to reduce bleeding risk – what safe options do I have?
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources